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Abstract: E2F1 becomes activated during the G1 phase of the cell cycle, and posttranslational modifications modulate its activity.
Activation of G-protein coupled receptors (GPCR) by many ligands induces the activation of adenylate cyclases and the production of
cAMP, which activates the PKA enzyme. Activated PKA elicits its biological effect by phosphorylating the target proteins containing
serine or threonine amino acids in the RxxS/T motif. Since PKA activation negatively regulates cell proliferation, we thought that
activated PKA would negatively affect the activity of E2F1. In line with this, when we analyzed the amino acid sequence of E2F1,
we found 3 hypothetical consensus PKA phosphorylation sites located at 127-130, 232-235, and 361-364 positions and RYET, RLLS,
and RMGS sequences. After showing the binding and phosphorylation of E2F1 by PKA, we converted the codons of Threonine-130,
Serine-235, and Serine-364 to Alanine and Glutamic acid codons on the eukaryotic E2F1 expression vector we had previously created.
We confirmed the phosphorylation of T130, S235, and S364 by developing monoclonal antibodies against phospho-specific forms of
these sites and showed that their phosphorylation is cell cycle-dependent. According to our results, PKA-mediated phosphorylation of
E2F1 by PKA inhibits proliferation and glucose uptake and induces caspase-3 activation and senescence.
Key words: E2F1, cell cycle, PKA, forskolin, senescence, proliferation

1. Introduction
E2F family members play an important role in the
regulation of the cell cycle and apoptosis. The first E2F
family member, later named E2F1, was identified as a
protein involved in the transcriptional regulation of the
adenoviral E2 gene (Kovesdi et al., 1986; Hazar-Rethinam
et al., 2011). After cloning the rest of the 7 members of
the E2F family and showing their associations with pRB,
the E2F family member was placed to the center of the
regulation of the cell cycle and development of cancer
(Bandara and La Thangue, 1991; Kaelin et al., 1992). E2F
family members are classified as transcriptional activators
(E2F1, E2F2, and E2F3a), repressor (E2F3b, E2F4, and
E2F5), and inhibitor (E2F6, E2F7a, E2F7b, and E2F8).
The expression of activator E2F members is regulated by
the cell cycle, and their level reaches to a maximum at
the G1/S phase of the cell cycle (DeGregori et al., 1995).
Although activator E2Fs are transcriptionally induced
during the G1/S phase, the repressor E2Fs are kept at basal
levels through the cell cycle and suppress the expression

of genes required during the S phase (Takahashi et al.,
2000). Meanwhile, the inhibitor E2Fs competitively bind
to both the activator and the inhibitor E2Fs and modulate
the cell cycle differently, depending on the cellular context
(Iaquinta and Lees, 2007).
E2F1 binds to the TTTSSCGCS consensus sequence
at the promoter of target genes by dimerizing with its
dimerization partners (DP) (Helin et al., 1993). The target
genes induced by E2F1 include CDC2, CDC25A, cyclin
D1, cyclin E, DHFR, DNA polymerase alpha, replication
factor-alpha (RFC3), and RAD52 (Slansky et al., 1993;
DeGregori et al., 1995; Ohtani et al., 1995; Inoshita et al.,
1999; Muller et al., 2001; Stanelle et al., 2002). In addition
to its role in the G1/S phase, E2F1 also plays an essential
role in slowing down the cycle in the absence of nutrients
and growth factors (Shan and Lee, 1994). Besides, E2F1
induces the p53-dependent and independent apoptosis
by inducing the expression of p53, ARF, Apaf1, ASPP1/2
(apoptosis stimulating protein of p53), and p73 (Qin et al.,
1994; Shan and Lee, 1994; Wu and Levine, 1994; Irwinet
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et al., 2000; Lindstrom and Wiman, 2003; Chenet et al.,
2005) and by suppressing the expression of NF-kB (Ma et
al., 2002).
In addition to its role in the regulation of the cell
cycle and apoptosis, E2F1 also controls the proliferation/
differentiation of neuronal cells and the development of
the neocortex (Mohan et al., 2012). Furthermore, E2F1
controls lipid metabolism by inducing the transcription
of SREBP (sterol regulatory element-binding protein)
and PPARg (Dali-Youcef et al., 2007). Also, E2F1 controls
the synthesis and secretion of insulin from the pancreatic
beta cells by inducing the expression of Kir6.2 (Blanch
et al., 2011), while also repressing glucose metabolism
by inducing the expression of pyruvate dehydrogenase
kinase 4 (PDK4) (Hsieh et al., 2008). E2F1 inhibits VEGF
expression under hypoxic conditions by inducing p53
(Berger et al., 2010), and induces expression of VEGF
receptors FLT1 (VEGFR1) and KDR (VEGFR2) under
oxygenic conditions (Pillai et al., 2010) and directly
regulates the expression of MMP9, MMP14, and MMP15
(Johnson et al., 2012).
Until 1989, it was largely accepted that the activity of
E2F1 was regulated by its inhibitor, pRB. In 1989, Bagchi et
al. showed that E2F1 can be activated by phosphorylation
(Bagchi et al., 1989). However, in the following years,
several groups of researchers showed that CDK-mediated
phosphorylation of E2F1 at different residues can either
increase or decrease its DNA and pRB binding affinities
(Peeper et al., 1995; Zhao et al., 2013). It was later shown
that during DNA damage, ATM and CHK2-mediated
phosphorylations of E2F1 at Serine 31, 364 facilitate the
binding of E2F1 to the promoters of proapoptotic genes
as well as 14.3.3 (Lin et al., 2001; Stevens et al., 2003). The
phosphorylation of E2F1 at Serine 403 and Threonine 433
has been shown to be carried out by different enzymes such
as p38, JNK1, and glycogen synthase kinase-3β (GSK3β).
The phosphorylation of these induces nuclear export and
stabilization of E2F1 (Wang et al., 1999; Garcia-Alvarez et
al., 2007; Ivanova et al., 2009).
In addition to phosphorylation, E2F1 also undergoes
acetylation at Lysine 117, 120, and 125 by p300, P/CAF,
and Tip60; these acetylations increase the ability of E2F1 to
bind to ADA2 and ASC2 (Marzio et al., 2000). E2F1 uses the
negative-feedback mechanism to control its own acetylation
by inducing the expression of deacetylase SIRT1. When
SIRT1 activity is inhibited, increased cell death is observed
in the p53-deficient cells after DNA damage (Pediconi et
al., 2009; Olmos et al., 2011). Although phosphorylation
and acetylation positively stimulate the function of E2F1,
E2F1 can also be methylated at Lysine 185, Arginine
111/113. All methylations induce ubiquitination and the
degradation of E2F1, while demethylated by lysine-specific
demethylase (LSD1) causes the stabilization of E2F1
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(Kontaki and Talianidis, 2010). Recently, it was shown
that E2F1 undergoes neddilation and ADP-ribosylation.
Neddylation causes destabilization of E2F1 and prevents
the proapoptotic and transcriptional activity of E2F1
during DNA damage. NEDD8 is removed by Sentrincysteine protease 8 (SENP8), and this reactivates E2F1 to
induce the transcription of proapoptotic genes (Aoki et al.,
2013). PARP1-mediated poly-ADP-ribosylation of E2F1
results in a pause in the cell cycle or induction of apoptosis
in the presence or absence of growth factors, respectively
(Kumari et al., 2015).
Cyclic AMP-activated kinase (PKA) is known for its
antiproliferative properties and claimed to be mediated
by different means. For example, Schmitt et al. showed
that cAMP-mediated inhibition of cell growth is mediated
by the phosphorylation of SRC by PKA (Schmitt and
Stork, 2002). Ferretti et al. showed that PKA is activated
shortly after the removal of glucose and activated PKA
phosphorylates AMPK and induces its antiproliferative
activity (Ferretti et al., 2016). Similar to this, it was recently
shown that GPCR-activated PKA phosphorylates the
raptor subunit of mammalian mTORC1 and modulates
the growth-promoting activity of mTORC1 (Jewell et
al., 2019). In addition to all of these findings, several
publications have also showed that the antiproliferative
activities of adiponectin, forskolin, and sildenafil are
mediated by the activation of PKA by these molecules
(Tantini et al., 2005; Medina et al., 2014).
As mentioned above, E2F1 can perform a dual
function during the cell cycle and can promote cell
growth or apoptosis, depending on the conditions of
growth media. Most of these dual functions seem to be
modulated by posttranslational modifications. Given that
the activation of PKA can have significant impacts on cell
proliferation and that proliferation is tightly regulated by
the cell cycle, we hypothesized that E2F1 could be a target
of PKA as E2F1 is primary responsible for the progression
of the cell cycle from the G1 to S phase. Indeed, when we
analyzed the amino acid sequence of E2F1, we found 3
putative PKA phosphorylation motifs (RXXS/T) located
at T130, S235, and S364. Therefore, we first tested whether
the PKA activator (forskolin) would affect the cellular
level of E2F1 and found that PKA activation with 20-uM
forskolin gradually reduced the cellular level of E2F1 for
at least 16 h. After this promising data, we mutated the
codons of the hypothetical PKA phosphorylation sites
T130, S235, and S364 to nonphosphorylatable Alanine
and to phosphorylate the mimicking Glutamic acid. We
then tested the effect of these mutants on cell proliferation,
expression of Ki67, induction of apoptosis, and glucose
uptake and senescence. Collectively, our results indicate
that while Glutamic acid mutants suppress proliferation,
Alanine mutants induce it, indicating that PKA-mediated
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phosphorylation of E2F1 shifts its activity. In line with
this, while Glutamic acid mutants induce the induction of
apoptosis, Alanine mutants repress apoptosis.
2. Materials and methods
2.1. Cell culture and biological reagents
Reagents were obtained from the following sources:
monoclonal anti-E2F1 and anti-GAPDH came from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The
monoclonal anti-GAPDH antibody was also from Santa
Cruz Biotechnology, Inc.; antirabbit HRP and antimouse
HRP were purchased from Bio-Rad Laboratories, Inc.
(Hercules, CA, USA). HEK293 cells were grown in DMEM
supplemented with 10% FBS, 100 mg/mL penicillin, 50 µg/
mL streptomycin, and 1 mM glutamine.
2.2. Cloning and side directed mutagenesis
Cloning primers:
Forward: 5’-ccggaattcgccgccatggccttggccggggcccctgcggg-3’
Reverse: 5’-ccggaattcgaaatccaggggggtgaggtccccaaagtc -3’
Mutagenesis primers:
T130,S235, and S364 of human E2F1 were mutated to
Alanin (T130A,S235A, and S364A) and Glutamic Acid
(T130E,S235E,S364E) with the Pfu polymerase (Thermo
Fisher Scientific Inc.,Waltham, MA, USA) using the
primers listed above. PCR conditions were 30 s at 95 °C,
followed by 18 cycles of 95 °C for 30 s, 56.5 °C for 1 min,
72 °C for 10 min, and 1 step of 72 °C for 10 min. Mutations
were verified by DNA sequencing (Supplemental Figures
S1–S3).
T130A Forward: 5’-agaagtcacgctatgaggcctcactgaatctgacc-3’
T130A Reverse: 5’-ggtcagattcagtgaggcctcatagcgtgacttct-3’
S235A Forward: 5’-ctgcgcctgctcgccgaggacactg-3’
S235A Reverse: 5’-cagtgtcctcggcgagcaggcgcag-3’
S364A Forward: 5’-tcccggatgggcgccctgcgggctcc-3’
S364A Reverse: 5’-ggagcccgcagggcgcccatccggga-3’
T130E Forward: 5’-gggagaagtcacgctatgaggagtcactgaatctgaccaccaa-3’
T130E Reverse: 5’-ttggtggtcagattcagtgactcctcatagcgtgacttctccc-3’
S235E Forward: 5’-cagctgcgcctgctcgaggaggacactgacagc-3’
S235E Reverse: 5’-gctgtcagtgtcctcctcgagcaggcgcagctg-3’
S364E Forward: 5’-gtcccggatgggcgagctgcgggctcccg-3’
S364E Reverse: 5’-cgggagcccgcagctcgcccatccgggac-3’
2.3. Transfections and treatments
Sixty to seventy percent confluent HEK293 cells were
transfected with 15 µg of mock or E2F1 expression vectors
prepared in pcDNA3.1. After 16 h, the cells were shocked
with medium containing 10% glycerol and cultured in
complete DMEM for 24 h. The cells were then serumstarved for 16 h and treated with reagents.
2.4. Immunoprecipitation and Western blot
Protein concentrations of whole cell lysates obtained in
lysis buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1.2%
Triton X-100, 1 mM EGTA, 1 mM EDTA, 1 mM PMSF,

0.15 U/mL aprotinin, 10g/mL leupeptin, 10g/mL pepstatin
A, and 1 mM sodium orthovanadate] were determined
using the Bradford method. Before immunoprecipitations,
lysates were precleared with 50-μL protein A/G-Agarose
beads (Santa Cruz Biotechnology, Inc., sc-2003). To
precipitate the protein complexes, 2-μg primary antibody
was added per 1-mg protein lysate, incubated for 2 h in +4
°
C nutator; then, protein A/G-agarose beads were added
and incubated overnight in +4 °C nutator. Beads were
pelleted by centrifugation at 6000×g for 1 min, washed
in cold lysis buffer at least 3 times, resuspended in SDS
sample buffer containing β-mercaptoethanol and boiled
for 5 min. Equal amounts of protein were fractionated by
SDS-PAGE on 10% polyacrylamide gels and transferred
overnight to Immobilon-P PVDF membranes. Blots
were probed with primary antibodies and corresponding
HRP-conjugated secondary antibodies, and proteins were
detected using Clarity ECL western blotting substrate
(Bio-Rad Laboratories, Inc., 1705061).
2.5.Cell viability testing and MTT procedure
To investigate the effects of wild type and mutants of E2F1
on proliferation of HEK293 cells, 3000 HEK293 cells were
reverse transfected with 300-ng vectors with lipofectamine
2000 in 96-well plates with 6 replicates in complete DMEM.
The cells were then incubated for 72 h. At the end of the
72 h, 20 µL of MTT (5 mg/mL) solution was added for 4 h
at 37 °C in an incubator. The medium was then removed,
and DMSO (100 µL) was added to dissolve the formazan
crystals. The plates were shielded from light using a foil
and left in an orbital shaker maintained at 600 revolutions/
minute for 5 m. The amount of MTT formazan product
formed was determined by measuring absorbance at 540
nm, with 690 nm as the reference wavelength.
2.6. Immunofluorescent in cell cultures: Ki67 staining
Ki67 (proliferation marker) staining in transfected
HEK293 cells was done by immunofluorescence (IF) assay.
Briefly, HEK293 cells were transfected with vectors and
24 h after transfection, the cells were plated at a density
of 3000 cells per well in a 96-well microtiter plate with 6
replicates. The cells were incubated for 72 h. After this,
fixed cells were incubated with primary antibody overnight
at 4 °C, followed by 1-h incubation with Alexa Fluor 594
(Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA) in the dark at 37 °C. Ki-67 monoclonal antibody
(cell signalling) was used at dilutions of 1:200 and 1:800,
respectively. Species- and subtype-matched antibodies
were used as negative controls [universal negative controls
for mouse or rabbit primary antibodies (Dako Denmark
A/S, Glostrup, Denmark)]. The coverslips were mounted on
the slides by using a Slow Fade Gold antifade reagent with
4′,6-diamidino-2-phenylindole (DAPI) (Life Technologies
Co., Carlsbad, CA, USA). Images from the IF slides were
obtained with an inverted microscope (Olympus IX51)
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with 20× magnification. For quantifying the number of
Ki67+, 3 pictures were randomly taken from each sample
in a blind manner.
2.7. Caspase 3 activation assays
Caspase 3 activity was assessed with colorimetric
caspase assay kits (Bio vision K106-200), according to
the manufacturer’s instructions. Briefly, HEK293 cells
were transiently transfected with vectors; at the 48th
hour of transfection, the cells was lysed with cellular lysis
buffer, then protein concentrations were determined.
Approximately 150-μg lysate volume was brought to 50
uL with cell lysis buffer, and 50-uL 2X reaction buffer
containing 10 mM of DTT was added. Lysates were either
incubated DEVD-pNA (200 uM) or IETD-pNA (200 uM)
for 2 h, and colorimetric measurements were taken at 405nm wavelength.
2.8. Glucose uptake assay
To determine whether Alanine and Glutamic acid mutants
would affect the glucose uptake after insulin stimulation,
we used a cell-based Glucose Uptake Assay Kit (Cayman
Chemical Company, Ann Arbor, MI, USA). Briefly,
3000 HEK293 cells were reverse transfected with 300-ng
vectors with lipofectamine 2000 in 96-well plates with 3
replicates in complete DMEM and cells were incubated for
24 h; at the end of incubation, we washed the cells with
glucose-free medium (Sigma-Aldrich Corp., St. Louis,
MO, USA, D5030). Then, the cells were incubated with
glucose free medium containing glucose analog 2-NGBD
in the presence and absence of insulin (100 ng/mL) in the
dark; subsequently, the medium was removed, the cells
were washed, and the 2-NBDG taken up by the cells was
detected using fluorescent filters with excitation 485 nm
and emission 535 nm. Fluorescein intensity was calculated
by using ImageJ analysis program.
2.9. Senescence assays
SA-β-Gal staining was performed using an Abcam Kit
ab65351 (Abcam PLC, Cambridge, UK) according to the
manufacturer’s specifications. Images were collected using
a Zeiss Primo Star microscope (Carl Zeiss Microscopy
GmbH, Oberkochen, Germany). The fraction of SA-βGal–positive cells was determined by counting the total
and SA-β-Gal–stained cell’s area in 3 to 6 fields (×40) per
treatment per cell line via an ImageJ analysis program.
2.10. Thymidine block (cell cycle arrest) and cell cycle
analysis
HEK293 cells were synchronized into the G1 phase by
releasing mitotic cells for 8 h, into S phase by a double
thymidine block (after incubation with 2 mM thymidine
for 16 h, the cells were washed and released into complete
media for 8 h, followed by another 16h of incubation with
2 mM thymidine), and into the G2 by releasing S phase
cells for 8 h. After thymidine blocking, the cells were
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treated with 10% FBS including medium for the specified
time. Cell cycle analysis was monitored by flow cytometry
by FACSCanto II (BD). Cells were fixed in 70% ethanol
and treated with RNase (100 µg/mL) before staining with
propidium iodide (50 μg/mL; Sigma-Aldrich Corp.). The
cells were then gated and the histogram function was
plotted in /(BD).
2.11. Development of monoclonal antiphospho E2F1
antibodies
Antibodies were made as previously described (Özeş et al.,
2018). Phosphopeptides of E2F1 (5-GVKSPGEKSREYHLMNICTTQLRLLpT130-SLNLTTKR-3,5’
pS235-EDTDSQR-3’:
5’-LEQEPLLSRMG-pS364LRAPVDEDR-3) were manufactured by IT-Technologies.
Approximately 100 ng of peptides dissolved in sterile
water was mixed with 100 ng of LPS, 100 uL of mineral oil,
and then vortexed for 30 s. Balb/C mice were immunized
intraperitoneally twice a week for 8 weeks. At the end of
the 8 weeks, the animals were sacrificed and their spleens
were removed; hybridomas were created with Fo cells
using PEG-4000. Then, 1/1000 times diluted hybridomas
were transferred in 96-well plates in 200 µL. The next day,
wells containing a single cell were marked, and these cells
were incubated for 2 weeks. At the end of this period, the
cells were transferred in T25 and further incubated for
30 days. Supernatants of these cells were collected and
antibodies in supernatants were purified by using Amicon
Pro Affinity Concentration Kit Protein A with 100 kDa
colon (ACK5100PA).
2.12. Statistical analysis
Statistical software SPSS and Graphpad Prism were
used. Comparison of parameters was performed using
the Wilcoxon signed-ranks test. A P value of <0.05 was
considered to be statistically significant.
3. Results
3.1. PKA activation destabilizes E2F1 and mutants of
E2F1 can be ectopically expressed
Since we postulated that E2F1 could be phosphorylated
at 3 different sites by PKA, we wanted to determine
whether this phosphorylation would have any effect on the
expression/stability of E2F1. For this, we first stimulated
HEK293 cells, grown in regular DMEM containing 10%
serum, with 20 mM of forskolin and prepared total cellular
lysates and determined the level of E2F1 by western
blotting. As shown in Figure 1A, forskolin treatment
caused a sharp drop in the E2F1 level during the 2nd
hour of poststimulation. Compared to the control cells,
forskolin treatment caused a slight increase at the 4th
hour and a gradual decrease of nearly 75% during the
16th hour of poststimulation. After the level during the
16th hour, E2F1 slowly increased and reached to control
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levels at the 48th hour of poststimulation. To validate
whether the observed results were due to PKA activation,
we preincubated HEK293 cells with a well-known PKA
inhibitor H9 (2.5mM) for 1 h before stimulation with
forskolin. As shown at Figure 1B, preincubation of
HEK293 cells with H9 completely abrogated the forskolininduced E2F1 downregulation/degradation. These results
clearly indicate that forskolin stimulation and activation
of PKA either destabilizes E2F1 or represses its expression.
Since we generated Alanine and Glutamic acid mutants
of E2F1, we wanted to show whether or not introduced
mutations would affect the ectopic expression/stability of
our mutants. To show this, we reverse transfected HEK293
cells with 6 µg of vectors using Lipofectamine 2000 for 48 h,
prepared total cell lysates, and determined the level of E2F1
by western blotting. As shown in Figures 1C and 1D, both
Alanine and Glutamic Acid mutants can be expressed at

very high levels for at least 48 h posttransfection. The blots
were overexposed in order to determine the level of fold
induction of mutants compared to the level of endogenous
E2F1. However, due to very high levels of expression of
mutants, we could not detect endogenous E2F1 at the time
the bands of the mutants were already bleached out. Since
we determined that expression of endogenous E2F1 is very
low compared to mutants, we did not try to suppress the
expression of endogenous E2F1 by si- or shRNA targeting
E2F1 for the remaining experiments.
3.2. PKA and E2F1 binds to each other and activation of
PKA causes decline in the protein level of E2F1
Since we hypothesized that E2F1 could be a target for PKA,
we wanted to show whether these 2 proteins bind to one
another. To do this, we performed immunoprecipitation
and immunoblotted the membranes with reciprocal

Figure 1. PKA activation destabilizes E2F1 and mutants of E2F1 can be ectopically expressed. (A) HEK293
cells were treated with forskolin (20 mM) and cellular lysates were collected for indicated times. Approximately
100-mg total protein lysates were fractionated on 10% SDS-PAGE and blot was labeled with an anti-E2F1
antibody. The blot was stripped off and relabeled with an anti-GAPDH antibody. Band intensities were
determined using ImageJ, and the relative abundance of the E2F1 level was determined by dividing E2F1
band intensities to that of GAPDH. (B) HEK293 cells were pretreated with PKA inhibitor H9 for 1 h, then
forskolin was added for indicated times and levels of E2F1; GAPDH relative change in expression of E2F1
was determined as mentioned. Band intensities were determined using ImageJ and relative abundance
of E2F1 level was determined by dividing E2F1 band intensities to that of GAPDH. (C,D) Subconfluent
HEK293 cells cultured DMEM in 100 mm plates were transfected with 30-ug expression vectors of Alanine
mutants (C) and Glutamic acid mutants (D) of E2F1 using calcium phosphate protocol for 48 h. Cellular
lysates were collected in lysis buffer and 100-ug total protein lysates were fractionated on 10% SDS-PAGE,
and the blot was labeled with an anti-E2F1 antibody. The blot was stripped off and relabeled with an antiGAPDH antibody (WT-E2F1 was used as a control in statistical analysis. “a”: statistically significant decrease,
P < 0.0001).
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antibodies. As shown in Figure 2A, there is a slight
association between E2F1 and PKA in the lysate of
untreated cells, and the treatment of cells with 20-uM
forskolin for 1 h significantly increased the binding of
these proteins to each other. After showing the binding,
we wanted to show whether PKA would phosphorylate
E2F1 under an in vitro condition. To test this, we
immunoprecipitated the wild type E2F1 from total cellular
lysate prepared from HEK293 cells overexpressing the
wild type E2F1. As shown in Figures2B–2C, E2F1 can be
effectively immunoprecipitated and phosphorylated by
PKA. The phosphorylated E2F1 is identified with anti-PKA
substrate antibody, and in vivo phosphorylated E2F1 band

in lysate is also evident (Figure 2C). From these results, we
concluded that PKA phosphorylates E2F1 under in vitro
and in vivo conditions.
3.3. PKA phosphorylation site mutants differentially
affect proliferation of HEK293 cells
Since the cAMP level goes up in response to deprivation of
glucose and nutrients, it is logical to think that activation
of PKA under such conditions serves as a defence
mechanism. Therefore, under such limiting conditions,
the rate of proliferation must be slowed down, and in
that respect, the cell cycle must be more tightly regulated
or repressed. Therefore, we postulated that Alanine and

Figure 2. PKA and E2F1 bind to each other, and activation of PKA causes a decline inthe protein level of E2F1.
(A,B) Physical interaction between E2F1 and PKA was explored with reciprocal immunoprecipitations. E2F1
and PKA were immunoprecipitated from untreated and 1 h- forskolin-treated HEK293 cells. E2F1 and PKA were
immunoprecipitated from 1mg of total cellular lysate and blotted with E2F1 and PKA antibodies. (C) In vitro
kinase reaction was performed with a PKA catalytic subunit. Wild type E2F1 was immunoprecipitated from 3-mg
total cellular lysate prepared from HEK293 cells overexpressing the wild type E2F1. After immunoprecipitation,
the pellet was washed 3 times in 1X PKA reaction buffer and resuspended in 50 mL of reaction buffer. It then
underwent in vitro kinase reaction with the addition of the PKA catalytic subunit PKAca (purchased from
NEB-P600S) and 10 mM ATP. The reaction mix was incubated for 30 min at 37oC. We terminated the reaction
by incubating the samples at 65 °C for 5 min, then washed the reaction mix according to the manufacturer’s
protocol; we then resuspended the pellet in SDS-loading dye, incubated it at 95 °C for 5 min, and fractionated
the supernatant and lysate in duplicates using 10% SDS-PAGE. Immunoblotting was performed with E2F1 and
an phospho-PKA substrate antibody.
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phosphorylation mimicking glutamic acid mutants of
E2F1 would affect the proliferation of cells differently.
To test this idea, we transiently transfected the human
HEK293 cells with all of the vectors and incubated the
cells for 72 h. We then determined cell viability using
MTT assay. As shown in Figure 3, ectopic expression of
wild type E2F1 diminishes proliferation of HEK293 cells
compared to mock transfected cells, and all Alanine
mutants, especially S235A, S364A, T130A/S235A,
and T130A/S364A mutants, not only prevented the
growth-suppressing effect of the wild type E2F1 but also
significantly induced the proliferation compared to mocktransfected cells. Moreover, the impact of glutamic acid
mutants is even more significant than Alanine mutants,
and single glutamic acid mutants diminished proliferation
by nearly 80% (Figure 3).
3.4. PKA phosphorylation site mutants differentially
affect expression of Ki67 in HEK293 cells
After showing the impact of Alanine and Glutamic acid
mutants of E2F1 on the proliferation of HEK293 cells,
we wanted to compare the effect of all mutants on the
expression of proliferation marker Ki67 in HEK293 cells.
As shown in Figure 4A, when we looked at the Alanine
mutants, we observed perfect alignment between the
rate of proliferation with the expression level of Ki67 in
HEK293 cells ectopically expressing expression S235A,
S364A, S235A/364A, T130A/S235A, and T130A/S364A.
However, ectopic expression of wild type E2F1 and T130E,
S235E, and S364E mutants significantly diminished the
expression of Ki67 compared to mock transfected cells;
these results are in complete agreement with the inhibition
rate of proliferation of these cells (Figure 4B). Collectively,
these results strongly suggest that phosphorylation of E2F1
by PKA at indicated sites dramatically changes the mode
of action of E2F1. While PKA-mediated phosphorylation
of E2F1 promotes a growth-suppressive effect, Alanine
mutants promote cell proliferation.
3.5.PKA phosphorylation site mutants differentially
affect caspase activation and glucose uptake
Since we observed that Glutamic acid and Alanine
mutants affected the proliferation of HEK293 in almost
the opposite way, we wanted to support our observations
by determining glucose uptake and activation of caspase-3
in HEK293 cells transiently expressing all mutants. As
shown in Figure 5A, ectopic expression of E2F1 slightly
increased caspase-3 activity compared to the mocktransfected cell; however, all Glutamic acid mutants, which
suppressed the proliferation of HEK293 cells, significantly
increased caspase-3 activity, while none of the Alanine
mutants induced caspase-3 activity. However, the glucose
uptake experiment yielded completely opposite data in
relation to caspase-3 activation. While all Alanine mutants
significantly induced glucose uptake, all of the Glutamic

Figure 3. PKA phosphorylation site mutants differentially
affect proliferation of HEK293 cells.
To determine the effect of Alanine and Glutamic acid mutants
of E2F1 on proliferation, HEK293 cells were reverse transfected
with 100 ng of mock and vectors in 96-well plates and
incubated for 72 h. Cell viability was determined using MTT
assay (WT-E2F1 was used as a control in statistical analysis.
“a”: statistically significant increase, P < 0.0001; “b”: statistically
significant increase, P < 0.0001).

mutants of E2F1 significantly reduced it, as can be seen in
Figure 5B. Taken together, our results strongly suggest that
under PKA-activating conditions, E2F1 is phosphorylated
by PKA, and this modification suppresses uptake of
glucose and pushes the cells toward activation of caspase-3
pathway and suppression of proliferation.
3.6. Synchronization of 293T cells using double
thymidine block
E2F1 activity is mainly induced during G1 by CDKmediated phosphorylation of pRB, and this activation
prepares cells to progress from the G1 to S phase. Since E2F1
activity is diminished after the G1 phase, it is important
to understand how this is achieved. To shed light on this,
we hypothesized that PKA-mediated phosphorylations of
E2F1 might play a role in the progression of the cell cycle.
To show this, we performed a double thymidine block
and arrested the cells at the end of G1, causing a release
by resuspending the cells in thymidine-free medium. Cell
cycle analysis was done using flow cytometry. As shown
in Figure 6, at the time of release (time zero), 32.4% and
41.5% of the cells were arrested at the Go/G1 and S phases,
respectively. The G1/S phase-arrested cells progressed very
quickly through the late G1 and S phases and at the end of
the 4th hour of postrelease, 32% and 45% of the cells were
at S and G2/M phases; only 10% of the cells remained at the
S phase at the end of the 8th hour of postrelease. At the end
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Figure 4. PKA phosphorylation site mutants differentially affect expression of Ki67 in HEK293 cells.
HEK293 cells were reverse transfected with 100 ng of mock and vectors in 96-well plates and incubated for 72 h. Then, Ki67
immunofluorescence staining was performed (Ki67: red; DAPI: blue; Merge: red and blue).

Figure 5. PKA phosphorylation site mutants differentially affect Caspase activation and Glucose uptake.
(A) HEK293 cells were reverse transfected with mock-, wild-type, or mutants of E2F1 for 48 h, and caspase-3 activity was
determined by colorimetric Caspase-3 activation assay (Bio vision K106-200). (B) HEK293 cells were reverse transfected with
mock-, wildtype, or mutants of E2F1 for 24 h in 96-well plates and incubated for 24 h. A Cayman Glucose Uptake Cell Based
Assay Kit was used to determine the level of glucose uptake (CTCF: corrected total cell fluorescence). (WT-E2F1 was used as a
control in statistical analysis. “a”: statistically significant decrease, P < 0.0001; “b”: statistically significant increase, P < 0.0001; “c”:
statistically significant decrease, P < 0.005).

of the 12th hour of postrelease, 70%, 13.9%, and 15.6% of
the cells were at G0/G1, S, and G2/M phases, respectively.
These results indicate that the double-thymidine block
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protocol arrests these cells very well at the late G1 and
early S phases, and progression through the S and G2/M
phases can be easily documented.
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Figure 6. Synchronization of 293T cells using double thymidine block.
HEK293 cells were synchronized by double-thymidine block for 48 h; then, the cells were washed with PBS and released by adding
complete DMEM (without thymidine). The cells were then collected at 0-2-4-6-8-12-16-20-24 h postrelease for propidium-iodide
staining; cell cycle analysis was done using flow cytometry.

3.7. E2F1 is phosphorylated by PKA at the G0/G1 stages
of the cell cycle
Based on above results, we wanted to determine whether
phosphorylation of E2F1 by PKA would align with
the progression of the cell cycle through the G0/G1-SG2/M phases. To test this, we developed monoclonal
antibodies against pT130, pS235, and S364 using
peptides,
(5’-GVKSPGEKSREY-pT130-SLNLTTKR3’:5’-HLMNICT TQLRLL-pS235-EDTDSQR-3’:5’LEQEPLLSRMG-pS364-LRAPVDEDR-3’)
for
immunization. To determine specificity of our antibodies,
we prepared lysates of the HEK293 cells untreated or
treated with forskolin (20 ug/mL) for 1 h, prepared the
lysates and fractionated 100-ug total protein using 10%
SDS-PAGE. The blots were labeled with 1/100 dilution of
supernatants of monoclonal hybrodomas. As shown in
Figure 7A, our antibodies detected the phosphorylated
forms of E2F1 at the indicated sites. After that, the
supernatants of the monoclonal hybrodomas were
collected, and antibodies in the supernatants were purified

using an Amicon Pro Affinity Concentration Kit Protein
A with 100 kDa colon (ACK5100PA). Commasie-blue
staining was performed after SDS-PAGE to examine
the protein content of purified antibodies (Figure 7B).
To further confirm our results, we ectopically expressed
Alanin mutants of E2F1 for 48 h, serum starved the cells
for 16 h, treated them with forskolin (20ug/mL) for 1h,
and performed western blotting using 100-ug total cell
lysates. As shown in Figures 7C–7E, forskolin treatment
induced 50% phosphorylations of T130 and S364 by
50%; Alanin mutants diminish these phosphorylations.
However, in this experiment we detected very little
increase in phosphorylation of S235, and its Alanin
mutant did not interfere with this. Also, since we could
not detect an endogenous E2F1 level due to the very high
level of mutants E2F1, we normalized the phosphoforms
to GAPDH to detect induced phosphorylation.
After confirming the specificity of our antibodies, we
used them to detect cell cycle-specific phosphorylations of
E2F1. As shown in Figure 7F, T130 and S364 are strongly
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phosphorylated at the 2nd hour of postrelease, and these
phosphorylations progressively declined. Contrary to
T130/S364, S235 phosphorylation was minimal at the
2nd hour of postrelease. However, phosphorylations of
all 3 amino acids started to increase toward the end of
the G2/M phases. Based on these results, we suggest that
PKA phosphorylates E2F1 at least at T130 and S364 at the
end of the G1 and early S phases. These phosphorylations
interfere with the growth-promoting effect ofE2F1 and
induces growth-supressing activity of the E2F1 until the
cells reach the end of the cell cycle.
3.8. PKA-mediated phosphorylation of E2F1 induces
senescence
Because we observed the opposite effect of Alanine and
Glutamic acid mutants of E2F1 on the proliferation of
HEK293 cells, we wanted to give further evidence to
explain this observation. For this, we tested the effect of
the transient expression of the wild type, Alanine, and
Glutamic acid mutants of E2F1 on the induction of cellular
senescence in HEK293 cells. After 48 h of expression
of these proteins, we stained the cells for senescenceassociated β-galactosidase activity using X-get al. Since we
performed all of the staining on the same plate, we used
HEK293 and the wild type E2F1 for both comparisons.
As shown in Figures 8A and 8B, ectopic expression of
wild type E2F1 induces 3 times more β-galactosidase
activity compared to mock-transfected cells; however,
all Alanine mutants dramatically inhibited induction of
β-galactosidase activity. Particularly, T130A, S235A, and
T130A/S364A mutants almost completely ablated the
induction of β-galactosidase activity. However, when we
looked at Glutamic acid mutants, with the exception of
S364E and T130E/S235E mutants, all mutants significantly
induced β-galactosidase activity. However, the levels of
inductions were less than that of wild type E2F1. These
results clearly indicate that the phosphorylation of E2F1
by PKA at indicated sites not only causes the induction of
apoptosis but also induces senescence.
4. Discussion
The discovery of E2F1 as an E1A-binding protein was a
breakthrough inthe regulation of the cell cycle. Until
the clarification of posttranslational modifications, pRB
remained the main regulator of E2F1 activity. However, in
the past 20 years, several posttranslational modifications
of E2F1 have been reported and, according to these
publications, modifications affect either the function or
the stability of E2F1 (Ertosun et al., 2016). In addition to
these studies, Bagchi et al. reported that cAMP-dependent
kinase (PKA)-mediated phosphorylation of E2F1 induced
its DNA-binding capacity. Although this has been known
since 1989, PKA-mediated phosphorylation sites and
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the significance of these phosphorylations on cellular
physiology have not been fully elucidated.
The cyclic AMP-dependent protein kinase (PKA) plays
a significant role in cellular physiology. Activation of PKA
is induced by cAMP, which is synthesized by adenylate
cyclase when the cellular glucose level drops. Therefore,
PKA is considered to be a glucose sensor. Activated PKA
elicits its activity on many cellular events such as the
uptake and metabolism of glucose (Jensen, 2007; Kaihara
et al., 2015), cell proliferation and progression of the cell
cycle throughG1 to S, and completion of the M phase
(Anghileri et al., 1999; Costanzo et al., 1999). Although
the involvement of PKA in these cellular events has been
documented, the molecular mechanism or molecular
target(s) behind these regulations have not yet been
addressed.
With this in mind and knowing that E2F1 is also
involved in the regulation of these cellular processes, we
wanted to determine whether the modifications of E2F1
by PKA would have an effect on cellular events such as
the proliferation, glucose uptake, and progression of
the cell cycle. As mentioned before, we found 3 putative
PKA-phosphorylation sites located at T130, S235, and
S364, and converted the codons of these amino acids
to nonphosphorylatable Alanine and phosphorylation
mimicking Glutamic acid on eukaryotic the E2F1
expression vector we created. Since the stability of
E2F1 seems to be affected by the previously mentioned
modifications, we first wanted to determine whether
adenylate cyclase activator forskolin-mediated activation
of PKA would have an effect on the stability of E2F1.
Indeed, as shown in Figure 1A, stimulation of HEK293 cells
with 20 mM forskolin affected stability and caused a 75%
drop in the E2F1 level at the 16th hour of poststimulation.
However, after 16 h, the E2F1 level gradually increased and
reached a basal level. To support the involvement of PKA
in the destabilization of E2F1, we pretreated HEK293 cells
with PKA inhibitor H9 for 1 h prior to forskolin treatment.
This pretreatment significantly inhibited the forskolinmediated destabilization/degradation of E2F1, as seen in
Figure 1B. These results clearly indicate that the activation
of PKA is responsible for the destabilization of E2F1.
After determining the effect of PKA activation on the
stability of E2F1, we next showed the expression levels
of all of the mutants of E2F1 in transiently transfected
HEK293 cells. As shown in Figures 1C and 1D, all
mutants of E2F1 were expressed at very high levels in
the HEK293 cells for at least 48 h. The expression levels
of E2F1 mutants were very high compared to the basal
level of expression. Therefore,we did not omit the basal
level of expression of E2F1 for other experiments. After
showing the ectopic expressions of all mutants, we wanted
to determine whether PKA and E2F1 would associate with
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Figure 7. E2F1 is phosphorylated by the PKA at G0/G1 stages of the cell cycle.
(A) To determine the specificity of antibodies in our antibodies, we treated serum-starved HEK293 cells with forskolin (20 uM) for
1h, and 100 ug of cell lysates was fractionated on 10%SDS-PAGE; blots were labeled with 1/200 dilutions of the supernatant of our
monoclonal hybridomas.(B) Coomasie-blue staining of purified supernatants of our monoclonal hybridomas by column. (C,D,E) We
ectopically expressed Alanine mutants of E2F1 for 48h; then, 100 ug of cell lysates were fractionated on 10% SDS-PAGE and blots were
labeled with corresponding antibodies. (F) HEK293 cells were synchronized by double-thymidine block for 48 h, released, and the
cellular lysates of the released cells were prepared between at 2–24 h. postrelease. 100 mg of total cell lysates were fractionated on 10%
SDS-PAGE. Immunoblot was first labeled with anti-E2F1 antibody (1:1000), stripped off, and relabeled with anti-pT130, anti-pS235,
and-pS364 antibodies (1:1000) and with antimouse HRP (1:5000). The bottom portion of the blot was also labeled with anti-GAPDH
as a loading control. Analysis of SDS-PAGE results: the fold changes in phosphorylation were determined by dividing ImageJ values
of band intensities of phospho-bands to that of the E2F1 (zero hour (0 h) protein level was used as a control in statistical analysis. “a”:
statistically significant increase, P < 0.0001; “b”: statistically significant decrease, P < 0.0001; “c”: statistically significant decrease, P =
0.0002).
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Figure 8. PKA-mediated phosphorylation of E2F1 induces senescence. HEK293 cells were reverse transfected with mock and vectors
in 96-well plates and incubated for 48 h. Senescence-associated β-galactosidase staining was then performed. Staining was determined
using ImageJ and analyzed with a GraphPad Prism (WT-E2F1 was used as a control in the statistical analysis. “a”: statistically significant
increase, P < 0.0001).

one another under normal growth conditions. To avoid
forced associations, we immunoprecipitated both proteins
from untransfected HEK293 cells, and immunoblots were
labeled with reciprocal antibodies. As anticipated, we
found strong in vivo associations of E2F1 and PKA even
in the absence of forskolin, indicating that E2F1 serves as
substrate of PKA under normal growth conditions. After
demonstrating the physical association, we used the same
samples to show direct phosphorylation of E2F1 by PKA
and found that PKA effectively phosphorylates E2F1 under
in vitro conditions, as seen in Figure 2C. Collectively, these
results clearly show that PKA binds to and phosphorylates
E2F1.
As we mention above, the main aim of our study was
to show that the antiproliferative activity of PKA could
be mediated, at least in part, by PKA-mediated E2F1
phosphorylation. Therefore, we focused on the impact
of PKA phosphorylation site mutants of E2F1 on cell
proliferation, apoptosis, senescence, and glucose uptake.
As anticipated, ectopic expression of all Alanine mutants
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induced the proliferation of HEK293 and induced the
expression of the proliferation marker of Ki67, as well as
glucose uptake. The same mutants suppressed Caspase-3
activation and senescence. Contrary to this, Glutamic acid
mutants produced almost completely opposite results.
Therefore, we suggest that PKA-mediated phosphorylation
of E2F1 induces a growth suppressive effect. Although
Alanine mutants are artificial proteins, the results produced
from these mutants strongly support our hypothesis.
E2F1 is sequestered in its inactive form during G0/
G1 by forming a complex with pRB and are released/
activated after CDK-mediated phosphorylation of pRB
at the G1 phase. The activated E2F1 prepares cells to
enter the S phase by inducing the expression of many
genes responsible for DNA synthesis and progression
of cell the cycle through the S-G2/M phases (Ertosun et
al., 2016). Since chemical modifications can affect the
function of E2F1 and because our Glutamic acid mutants
inhibited cell proliferation and induced senescence, we
wanted to determine the exact time point at which E2F1
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phosphorylation takes place during the cell cycle. To
address this, we first developed monoclonal antibodies
against phosphopeptides of E2F1 bearing pT130, pS235,
and pS364. Next, we synchronized HEK293 cells by using
a double-thymidine block, which arrests cells at the end
of the G1 and early S phases (Chen and Deng, 2018).We
determined the phases of the cell cycle by using propidium
iodide staining. After determining the phases of the cell
cycle, we prepared the protein lysates of cells synchronized
the same way and for the same time points and labeled the
immunoblots using our monoclonal antibodies. As shown
in Figure 7F, T130 and S364 were heavily phosphorylated
immediately after the release of cells from the thymidine
block. These phosphorylations gradually declined. These
results indicate that PKA targets E2F1 at the late G1 and
early S phases. However, these phosphorylations were
kept at a minimal level during the S and G2/M phases.
Contrary to T130 and S364 phosphorylations, PKA does
not seem to phosphorylate S235 heavily, although the
phosphorylation pattern of S235 is very similar to T130
and S364. Since PKA-induced phophorylations seem to
suppress the proliferation inducing activity of E2F1, our

results are in good agreement with the required activity of
E2F1 during the S phase.
Collectively, our results suggest that E2F1 serves as a
substrate of PKA under in vivo conditions. In addition,
PKA-mediated phosphorylations of E2F1 may be used to
silence the growth-promoting activity of E2F1 after the
completion of the G1 and S phases. In this way, the cell
is prepared to enter G0 for initiation of another cell cycle.
Our results significantly contribute to our understanding
of the molecular mode of action of E2F1 as the master
regulator of the cell cycle. This explains how PKA-mediated
phosphorylation of E2F1 causes the suppression of cell
proliferation, suppression of glucose uptake, and induction
of caspase-3 activation and senescence in HEK293 cells.
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